CE IVD-marked SepsiTest™ is currently the only direct molecular diagnostic test which identifies far more than the most common blood pathogens.

SepsiTest™ relies on universal 16S/18S rRNA gene PCR and sequencing which identifies more than 345 bacteria and fungi.

As a supplement to SepsiTest™, Universal Microbe Detection, including UMD-Tissue, UMD-Liquid, UMD-Swab, UMD-Universal kits enable next to blood also the diagnosis of other body fluids, tissues, swabs and biofilms:

Body fluids

Blood

Synovial fluid

Cerebrospinal fluid

Ascites fluid

Bronchoalveolar lavage

Pleural fluid

Blood culture

Smear

Abscesses

Tissues

Heart valve

Liver biopsies

Brain biopsies and others

Process

SepsiTest™ is an “all-in-one” kit concept, including buffers, reagents and tubes necessary for DNA extraction and PCR/Real-Time PCR analysis. The consumables are guaranteed free of contaminating microbial DNA. No more than standard molecular laboratory equipment is needed to perform the test. Optionally, automated versions, SepsiTest™ SelectNA and UMD-SelectNA, are available for the extraction of microbial DNA from various specimens. SepsiTest™ SelectNA and UMD-SelectNA substantially reduce hands-on-time and the risk of contamination by handling.

Workflow:

Removal of human DNA and free floating DNA from dead microorganisms

Isolation of enriched bacterial and fungal DNA

Detection: In two separate reactions, bacterial and fungal DNAs are detected by 16S and 18S rRNA gene PCR or Real-Time PCR

Sequence analysis of amplicons from positive PCR testing is aided by a free online BLAST tool.

The tool (www.sepsitest-blast.net) is based on more than 7,000 quality-controlled sequence entries of the 16S/18S rRNA genes making identification of bacterial, Candida spp., Cryptococcus spp., andAspergillus spp. very precise.

Sensitivity

Spiking experiments show high analytical sensitivities of pathogens. For instance, sensitivities of Staphylococcus aureus and Candida albicans are <20 cfu/ml and <10 cfu/ml blood, respectively.

A number of studies, including the diagnosis of sepsis, endocarditis, meningitis and other diseases have proven that, compared with blood culture, SepsiTest™/UMD show good diagnostic values ​​and identify non-growing pathogens in patients who are treated with antibiotics and are blood culture-negative.

If you need more detailed information, a publication record, a first user trial offer or a presentation in your laboratory, please contact the Molzym support team.

Molzym announces CE IVD marking of their robotic microbial DNA isolation and direct PCR test, Micro-Dx™, for routine pathogen diagnosis.
With Micro-Dx™ Molzym introduces its latest development of products in line with SepsiTest™-UMD which was released in 2008.
“By Molzym’s proprietary robot ... more

Seegene and Molzym announced a partnership on the automated Magicplex™ Sepsis, a new multi-pathogen screening test capable of quick and accurate identification of over 90 leading sepsis-causing pathogens.
"The Magicplex Sepsis Test will be the new gold standard for performing accurate, rapi ... more

Molzym has developed in collaboration with NorDiag ASA the first automated platform worldwide for the culture-independent universal identification of microorganisms from whole blood. Clinical studies have shown that a high proportion of microbial infections are not detectable by conventiona ... more

Culture-inde¬pend¬ent molecular identification is a straight forward approach for the rapid pathogen identification, including fastidious and antibiotic-inhibited microorganisms. CE-IVD UMD-Universal has been evaluated using primary sterile body flui more

Company
Molzym was founded as a privately owned enterprise in Bremen, North-West Germany, in 2003. Ever since its foundation, Molzym was committed to develop innovative solutions to serve biological research and diagnosis of infectious diseases. Products range from pre-analytical kits for ... more